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LETTER TO THE EDITORS




In their letter Chatauret et al. [1] address an interesting
issue: in hypothermic machine perfusion for kidney pres-
ervation we should have a better understanding of the
machine effects versus solution effects.
During the discussions concerning the study design the
scientific steering committee also discussed which preser-
vation solutions should be used.
For more than 40 years, KPS-1 is the standard solution
for clinical machine perfusion. An increasing number of
animal experimental studies demonstrate that machine
perfusion with either HTK [2] or UW [3] leads to good
results. Nevertheless clinical data are missing so we
decided to use the standard solution.
For static cold storage use of HTK or UW is clinical
reality in the Eurotransplant region. Therefore both solu-
tions were accepted for cold storage in the trial.
Vaziri [3] performed an experimental study in a por-
cine autotransplantation model with 60 min warm ische-
mia and 24 h hypothermic preservation. Four Groups
were compared: Machine perfusion was with either KPS1
or UW and Cold storage with either KPS1 or UW.
Since no animal in the group with cold storage and
UW survived, the authors concluded that UW is bad for
kidney preservation because of its potassium content. In a
similar autotransplantation model with 60 min warm
ischemia but 4 h hypothermic treatment [4] we found
different results: four of seven animals survived with cold
storage in UW. Somehow dissociated the Chatauret et al.
interprete the group with machine perfusion and UW.
This group has the highest survival whereas the differ-
ences between MP with KPS1 and CS with KPS1 were
not so ‘‘obvious.’’ You would expect the deleterious effect
of a preservation solution to be aggravated by MP that
permanently exposes kidney parenchyma to the preserva-
tion solution.
Chatauret et al. expect ‘‘extrapolating from their results
that UW solution in the CS arm of the multicenter trial
pulls down the survival curve.’’ This is pure speculation.
Of all the experimental and clinical trials up to now at
least no inferior results have been shown for UW com-
pared with HTK [5,6].
We actually analyzed the results in the ECD subgroup
of the multicenter trial comparing UW and HTK pre-
served kidneys. There were no significant differences for
DGF rates (25% UW vs. 33% HTK), PNF rates (10%
UW vs. 13, 9% HTK) and 1 year graft survival (90% UW
vs. 78% HTK).
Chatauret et al. remind us that in experiments designed
to compare two conditions only one parameter must
change between the two conditions. An experimental ani-
mal DCD model with long, warm ischemia times and
preservation times seems to change more than one
parameter, compared with our clinical study.
The authors also see a ‘‘clear superiority of MP over
CS in their study independent of the solution used.’’
We do not see a reason to question our conclusions
concerning MP.
Although new solutions belong to the most interesting
developments in transplantation, from our point of view
multicenter trials comparing different solutions in
machine perfusion are not realizable in the next few years
without additional data.
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